Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4)¶ Protocol for a controlled clinical trial developed by consensus of an internati

Abstract:General design: Presentation of a new type of a study protocol for evaluation of the effectiveness of an immune modifier (rhG-CSF, filgrastim): prevention of postoperative infectious complications and of sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). This part describes the design of the randomised, placebo controlled, double-blinded, single-centre study performed at an university hospital (n = 40 patients for each group).¶Objective: The trial design includes the following elements for a prototype protocol:¶ - The study population is restricted to patients with colorectal cancer, including a left sided resection and an increased perioperative risk (ASA 3 and 4).¶ - Patients are allocated by random to the control or treatment group.¶ - The double blinding strategy of the trial is assessed by psychometric indices.¶ - An endpoint construct with quality of life (EORTC QLQ-C30) and a recovery index (modified Mc Peek index) are used as primary endpoints. Qualitative analysis of clinical relevance of the endpoints is performed by both patients and doctors.¶ - Statistical analysis uses an area under the curve (AUC) model for improvement of quality of life on leaving hospital and two and six months after operation. A confirmatory statistical model with quality of life as the first primary endpoint in the hierarchic test procedure is used. Expectations of patients and surgeons and the negative affect are analysed by social psychological scales.¶Conclusion: This study design differs from other trials on preoperative prophylaxis and postoperative recovery, and has been developed to try a new concept and avoid previous failures.¶

[1]  I. Celik,et al.  Cardiovascular adverse effects of antimicrobials in complex surgical cases. , 1996, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[2]  D. Hommes,et al.  Efficacy of recombinant granulocyte colony‐stimulating factor (rhG‐CSF) in experimental colitis , 1996, Clinical and experimental immunology.

[3]  W. S. Smith,et al.  Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. , 1995, Blood.

[4]  R. Moreno,et al.  Nine equivalents of nursing manpower use score (NEMS) , 1997, Intensive Care Medicine.

[5]  Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Marshall,et al.  Should morbidity replace mortality as an endpoint for clinical trials in intensive care? , 1995, The Lancet.

[7]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[8]  R. Lefering.  Biostatistical aspects of outcome evaluation using TISS-28. , 1999, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[9]  R. Haley,et al.  Identifying patients at high risk of surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination. , 1985, American journal of epidemiology.

[10]  T. Kaptchuk,et al.  Powerful placebo: the dark side of the randomised controlled trial , 1998, The Lancet.

[11]  Meyer Saklad,et al.  GRADING OF PATIENTS FOR SURGICAL PROCEDURES , 1941 .

[12]  M. Lawton.  Quality of life and affect in later life. , 1996 .

[13]  J. Solomkin.  Very large-scale, randomized, clinical trials in sepsis and septic shock. , 1994, Critical care medicine.

[14]  T. Habermann,et al.  Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. , 1997, The New England journal of medicine.

[15]  K C Cain,et al.  Measuring Preferences for Health States Worse than Death , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  J. Marshall,et al.  Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. , 1997, Archives of surgery.

[17]  W. Knaus,et al.  What Determines Prognosis in Sepsis? Evidence for a Comprehensive Individual Patient Risk Assessment Approach to the Design and Analysis of Clinical Trials , 1994 .

[18]  S M Shortell,et al.  The Performance of Intensive Care Units: Does Good Management Make a Difference? , 1994, Medical care.

[19]  Perioperative cardiac morbidity , 1990, Anesthesiology.

[20]  Ross Camidge,et al.  The European Organisation for Research and Treatment of Cancer , 2002 .

[21]  W. Nothdurft,et al.  Cytokines and progenitor cells of granulocytopoiesis in peripheral blood of patients with bacterial infections , 1995, Infection and immunity.

[22]  A Howell,et al.  The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Schibler,et al.  A Randomized, Placebo-Controlled Trial of Granulocyte Colony-stimulating Factor Administration to Newborn Infants With Neutropenia and Clinical Signs of Early-onset Sepsis , 1998, Pediatrics.

[24]  J. Wyatt,et al.  Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4)¶ Protocol of a controlled clinical trial developed by consensus of an internation , 2001, Inflammation Research.

[25]  H. Troidl.  Surgical research : basic principles and clinical practice , 1998 .

[26]  Stephen L. George,et al.  Fundamentals of Clinical Trials. (2nd ed.). , 1987 .

[27]  D. Sackett.  Evidence-Based Medicine: How to Practice and Teach EBM , 2018 .

[28]  J. Reynolds,et al.  Manipulation of local and systemic host defence in the prevention of perioperative sepsis , 1995, The British journal of surgery.

[29]  H. Kehlet,et al.  Circadian variation in unexpected postoperative death , 1992, The British journal of surgery.

[30]  H. Sitter,et al.  Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4)¶ Protocol of a controlled clinical trial developed by consensus of an internatio , 2001, Inflammation Research.

[31]  W. Knaus,et al.  African-American and white patients admitted to the intensive care unit: is there a difference in therapy and outcome? , 1995, Critical care medicine.

[32]  A. Wechsler,et al.  How to Choose a Relevant Endpoint , 1998 .

[33]  M. Koller,et al.  Quality of life research in patients with rectal cancer: traditional approaches versus a problem-solving oriented perspective , 1998, Langenbeck's Archives of Surgery.

[34]  Douglas G Altman,et al.  Better reporting of randomised controlled trials: the CONSORT statement , 1996, BMJ.

[35]  M. Edmonds,et al.  Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection , 1997, The Lancet.

[36]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[37]  N. Denzin,et al.  Handbook of Qualitative Research , 1994 .

[38]  Paterson Rl,et al.  Sepsis and the systemic inflammatory response syndrome. , 2000, Journal of the Royal College of Surgeons of Edinburgh.

[39]  G. W. Snedecor.  Statistical Methods , 1964 .

[40]  D. Watson,et al.  Health complaints, stress, and distress: exploring the central role of negative affectivity. , 1989, Psychological review.

[41]  M. Fink,et al.  Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs. , 1993, The Journal of trauma.

[42]  D. Cullen,et al.  Therapeutic Intervention Scoring System: Update 1983 , 1983, Critical care medicine.

[43]  H. Dudley.  Extracranial-intracranial bypass, one; clinical trials, nil. , 1987 .

[44]  L. Thuler,et al.  Risk factors for infectious complications after abdominal surgery for malignant disease. , 1996, American journal of infection control.

[45]  H. Troidl,et al.  Duration of antibiotic treatment in surgical infections of the abdomen. Introduction--the different ways to reach consensus. , 1996, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[46]  K. Asadullah,et al.  Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.

[47]  D. Watson,et al.  Development and validation of brief measures of positive and negative affect: the PANAS scales. , 1988, Journal of personality and social psychology.

[48]  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997 .

[49]  H. Troidl.  Quality of Life: A Relevant Endpoint , 1991 .

[50]  T. Hartung,et al.  Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. , 1992, Journal of immunology.

[51]  S. Satterfield,et al.  Disability and cognitive impairment are risk factors for pneumonia-related mortality in older adults. , 1993, Public health reports.

[52]  P. Guillou.  Adjuvant biological response modifiers after major surgery or trauma , 1995, The British journal of surgery.

[53]  W. Lorenz,et al.  Strahlentherapie bei chirurgischen und nichtchirurgischen Patienten Therapieerwartungen, Lebensqualität und Arzteinschätzungen , 1998, Der Chirurg.

[54]  Stephen G. West,et al.  A primer of social psychological theories , 1980 .

[55]  S. Nelson.  Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  R. Bone,et al.  Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS) , 1996, Annals of Internal Medicine.

[57]  N. Aaronson,et al.  The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. , 1998 .

[58]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[59]  H. Wulff,et al.  Surgical Research around the World , 1998 .

[60]  W Lorenz,et al.  Symptom reporting in cancer patients II , 1999, Cancer.

[61]  J. Kalden,et al.  Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy , 1993 .

[62]  E. Draper,et al.  Improving intensive care: Observations based on organizational case studies in nine intensive care units A prospective, multicenter study , 1993, Critical care medicine.

[63]  W. J. Hughes,et al.  Postoperative morbidity and mortality following resection of the colon and rectum for cancer , 1995, Diseases of the colon and rectum.

[64]  M. Malangoni,et al.  The risk of infection after colon injury. , 1986, Surgery.

[65]  M. Somerfield,et al.  Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Bone,et al.  Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. , 1996, Critical care medicine.

[67]  E. Masini,et al.  Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine , 1997, Inflammation Research.

[68]  W. Schaufeli,et al.  Simplified Therapeutic Intervention Scoring System: the TISS-28 items--results from a multicenter study. , 1996 .

[69]  W. Lorenz,et al.  H1 and H2 blockade: a prophylactic principle in anaesthesia and surgery against histamine-release responses of any degree of severity: Part II. , 1985, New England and regional allergy proceedings.

[70]  H J Tagnon,et al.  The European Organization for Research on Treatment of Cancer. , 1986, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[71]  DeLURY Db,et al.  Analysis of Covariance , 2020, Handbook of Regression Analysis With Applications in R.

[72]  K. Sarafidis,et al.  Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and β2 integrin expression Results of a randomized controlled trial , 1998, European Journal of Pediatrics.

[73]  D. DeMets,et al.  Fundamentals of Clinical Trials , 1982 .

[74]  U. Wolters,et al.  ASA classification and perioperative variables as predictors of postoperative outcome. , 1996, British journal of anaesthesia.

[75]  R. Gamelli,et al.  Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. , 1998, Critical care medicine.

[76]  M. Bronchud.  Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: five years on. , 1994, Oncology.

[77]  W. Lorenz.  Outcome: Definition and Methods of Evaluation , 1998 .

[78]  E. Schneider,et al.  Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. , 1996, Cytokine.

[79]  Per Nystr.  Proposed Definitions for Diagnosis, Severity Scoring, Stratification, and Outcome for Trials on Intraabdominal Infection , 2022 .

[80]  Why sepsis trials fail. , 1996, JAMA.

[81]  T. Hartung,et al.  Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. , 1995, Blood.

[82]  Marija J. Norusis,et al.  SPSS for Windows, Advanced Statistics, release 6.0 , 1993 .

[83]  Writing a Scientific Paper , 1998 .

[84]  H. Sitter,et al.  Clinic modelling randomised trials (CMRT’s) in animals as a new intermediate between biological experiments and randomised clinical trials: Application to antihistamine prophylaxis in anaesthesia and surgery , 1998, Inflammation Research.

[85]  P. Nyström,et al.  The systemic inflammatory response syndrome: definitions and aetiology. , 1998, The Journal of antimicrobial chemotherapy.

[86]  P. Wernet,et al.  Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. , 1995, Journal of critical care.

[87]  F. Keeling,et al.  Significant risk factors in elective colorectal surgery. , 1995, Annals of the Royal College of Surgeons of England.

[88]  H. Volk,et al.  G-CSF - an anti-inflammatory cytokine , 1995 .

[89]  G. Bernard,et al.  Sepsis trials. Intersection of investigation, regulation, funding, and practice. , 1995, American journal of respiratory and critical care medicine.

[90]  D. Mangano.  Anesthetics, coronary artery disease, and outcome: unresolved controversies. , 1989, Anesthesiology.

[91]  F. Mosteller,et al.  Experimental Methods: Clinical Trials , 1991 .

[92]  S. Belknap,et al.  A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998 .

[93]  James W. Pennebaker,et al.  The psychology of physical symptoms , 1982 .

[94]  W. Lorenz,et al.  [Preoperative risk assessment with the ASA classification. A prospective study of morbidity and mortality in various ASA classes in 2,937 patients in general surgery]. , 1992, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[95]  J. Armitage,et al.  Clinical applications of hematopoietic growth factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  M. Heinzelmann,et al.  SEPSIS AND SEPTIC COMPLICATIONS IN THE SURGICAL PATIENT: WHO IS AT RISK? , 1996, Shock.

[97]  J. Civetta,et al.  Therapeutic intervention scoring system: a method for quantitative comparison of patient care. , 1974, Critical care medicine.

[98]  L. Frumkin.  Role of granulocyte colony‐stimulating factor and granulocyte‐macrophage colony‐stimulating factor in the treatment of patients with HIV infection , 1997, Current opinion in hematology.

[99]  A S Elstein,et al.  Forecasting Survival in the Medical Intensive Care Unit: A Comparison of Clinical Prognoses With Formal Estimates , 1993, Methods of Information in Medicine.

[100]  H. Thaler,et al.  Direct observations of surgical wound infections at a comprehensive cancer center. , 1995, Archives of surgery.

[101]  H. Sitter,et al.  Randomised study comparing a non-ionic with an ionic contrast medium in patients with malignancies: First answer with a new diagnostic approach , 1999, Inflammation Research.

[102]  R A Weinstein,et al.  Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. , 1996, JAMA.

[103]  Douglas G Altman,et al.  How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing , 1999, The Lancet.

[104]  David E. Matthews,et al.  Using and Understanding Medical Statistics , 1984 .

[105]  A. Barkun,et al.  Measuring postoperative complications in general surgery patients using an outcomes-based strategy: comparison with complications presented at morbidity and mortality rounds. , 1997, Surgery.

[106]  D. Green,et al.  Immune Consequences of Trauma, Shock, and Sepsis: Mechanisms and Therapeutic Approaches , 1989 .

[107]  C. Ohmann,et al.  Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia , 1994, The Lancet.

[108]  C. Sprung,et al.  Why have new effective therapies for sepsis not been developed? , 1994, Critical care medicine.

[109]  D. Kuritzkes,et al.  Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial , 1998, AIDS.

[110]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[111]  B. Genetet,et al.  Impaired Leucocyte Functions in Diabetic Patients , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[112]  R. Bone.  Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. , 1995, JAMA.

[113]  R. Dellinger.  Post hoc analyses in sepsis trials: a formula for disappointment? , 1996, Critical care medicine.

[114]  H. Sitter,et al.  Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. , 1994, Surgery.

[115]  James R. Allen,et al.  Good Care of the Dying Patient , 1996 .

[116]  W. Sibbald,et al.  Round table conference on clinical trials for the treatment of sepsis. , 1995, Critical care medicine.

[117]  A. Spriet,et al.  Good practice of clinical drug trials , 1992 .

[118]  L. Way,et al.  Long-term cardiac prognosis following noncardiac surgery , 1992 .

[119]  W. Browner,et al.  Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. , 1992, JAMA.

[120]  A. Sauaia,et al.  Early Risk Factors for Postinjury Multiple Organ Failure , 1996, World Journal of Surgery.

[121]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[122]  Relman As,et al.  Assessment and accountability: the third revolution in medical care. , 1988 .

[123]  J. Wade.  Extracranial-intracranial bypass, one; clinical trials, nil , 1987 .

[124]  J. Chang,et al.  Haemopoietic cell kinetics in humans treated with rGM‐CSF , 1992, International journal of cancer.

[125]  C. Natanson,et al.  Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis , 1994, Annals of Internal Medicine.

[126]  D. Fairclough.  Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. , 1997, Statistics in medicine.

[127]  S. McKelvey,et al.  Auditing perioperative mortality. , 1987, Annals of the Royal College of Surgeons of England.

[128]  E. Rackow,et al.  Relationships between plasma cytokine concentrations and leukocyte functional antigen expression in patients with sepsis , 1994, Critical care medicine.

[129]  J. Vincent.  Search for effective immunomodulating strategies against sepsis , 1998, The Lancet.

[130]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[131]  J. Meakins,et al.  Antibiotic Trials in Intra‐abdominal Infections: A Critical Evaluation of Study Design and Outcome Reporting , 1984, Annals of surgery.

[132]  T. Okamura,et al.  Granulocyte colony-stimulating factor and platelet aggregation , 1993, The Lancet.

[133]  M. Koller,et al.  Symptom reporting in cancer patients: The role of negative affect and experienced social stigma , 1996, Cancer.

[134]  Christopher Boorse,et al.  Health as a Theoretical Concept , 1977, Philosophy of Science.

[135]  Prediction of postoperative outcome from perioperative changes of mediators in cholecystectomy - an application of Bayes' Theorem , 1999, Inflammation Research.

[136]  E P Steinberg,et al.  Comparison of the Rating Scale and the Standard Gamble in Measuring Patient Preferences for Outcomes of Gallstone Disease , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[137]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[138]  D. Mangano.  Preoperative Risk Assessment: Many Studies, Few Solutions: Is a Cardiac Risk Assessment Paradigm Possible? , 1995, Anesthesiology.

[139]  G. Mclauchlan,et al.  Outcome of patients with abdominal sepsis treated in an intensive care unit , 1995, The British journal of surgery.

[140]  G. Pierer,et al.  Can ASA grade or Goldman's cardiac risk index predict peri‐operative mortality? A study of 16 227 patients , 1997, Anaesthesia.

[141]  M. Fink.  Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections. , 1995, Critical care medicine.

[142]  C. Nies,et al.  Expectations and quality of life of cancer patients undergoing radiotherapy , 2000, Journal of the Royal Society of Medicine.

[143]  H. Iro,et al.  Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. , 1991, Blood.

[144]  S. Deventer,et al.  Modulation of Cytokine Release and Neutrophil Function by Granulocyte Colony-Stimulating Factor During Endotoxemia in Humans , 1997 .